Arabidopsis MC1 as a potent disaggregase of neuropathological aggregates
Advantages
- Integrates bioinformatics, molecular biology, and protein biochemistry to explore AtMC1’s disaggregating properties for NDDs.
- Unexplored potential of plant proteins like AtMC1 as therapeutics for NDDs, leveraging plants’ efficient protein maintenance.
- Early targeting of protein aggregation, a key hallmark across many NDDs.
Goal
The group is looking for a license agreement, but other collaborations may be considered.
Patent
International Patent Application (EP23382624.7)
Reference
UBTT0492-E
Contact
Rosa Vázquez Fresno (FBG-UB)
Email: rvazquez@fbg.ub.edu
Carlos Muñoz (CRAG)
Email: carlos.munoz@cragenomica.es
Arabidopsis MC1 as a potent disaggregase of neuropathological aggregates
Executive summary
A research group, with wide experience on immunology, has generated a novel therapeutic solution for neurodegenerative disease by utilizing Arabidopsis Metacaspase I (AtMC1) to break down pathological protein aggregates in the central nervous system.
The group is looking for a license, but other collaborations may be considered.
Introduction
NDDs are characterized by progressive neuron loss and pathological protein aggregation which affect millions globally.
Current therapies mainly address symptoms, not the root cause of NDDs
Description
- Design and test efficient AtMC1 variants using synthetic biology and protein engineering against aggregates linked to various NDDs (e.g., Alzheimer’s, Huntington’s).
- Potential to revolutionize early-stage NDD treatment and improve patients’ lives.
- Transfer technology to the pharmaceutical industry to accelerate clinical trials and market introduction.
Current stage of development
